Relevance of Maintenance Therapy Using Lenalidomide (Revimid) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).

Trial Profile

Relevance of Maintenance Therapy Using Lenalidomide (Revimid) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 24 Feb 2017 According to a Celgene Corporation media release,the European Commission approved REVLIMID as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation.
    • 22 Feb 2017 According to a Celgene Corporation media release, based on the data from this and other phase III study (Profile 700001712), the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID (lenalidomide) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT).
    • 21 Feb 2017 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top